Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Glucose absorption in intestine" is not itself a molecular target but describes a physiological process primarily mediated by specific transporters. The key molecular target responsible for intestinal glucose absorption is Sodium-glucose cotransporter 1 (SGLT1). This transporter is located on the apical membrane of enterocytes lining the small intestine and mediates active uptake of dietary glucose from the lumen into cells using energy from sodium gradients[4][6]. After entry via SGLT1, glucose exits into circulation through basolateral facilitative transporters such as GLUT2[2][3]. SGLT1 also plays an essential role in glucose-induced incretin hormone secretion—notably GIP and GLP‑1—which are important for insulin release after meals[2]. Loss or inhibition of SGLT1 drastically reduces both intestinal glucose uptake and incretin responses[2][3]. While GLUT2 has been proposed to contribute to bulk facilitated diffusion under high luminal concentrations, evidence indicates that SGLT1 remains indispensable even at high loads, with GLUT2's main role being basolateral exit rather than apical entry under most physiological conditions[3][5]. The query refers to "Glucose absorption in intestine" as if it were a single molecule or receptor. In reality, this term describes a process involving multiple proteins—primarily Sodium-glucose cotransporter 1 (SGLT1) but also including others like GLUT2. For structured data purposes, it should be mapped specifically to "Sodium-glucose cotransporter 1," not left as an unstructured process name[4][6].
Inhibitors block active sodium-coupled glucose uptake at the apical membrane, reducing postprandial blood glucose rise.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium-glucose cotransporter 1 (SGLT1).